LSD1 Antibody (2D6): sc-136174
- LSD1 Antibody (2D6) is a mouse monoclonal IgG κ provided at 200 µg/ml
- raised against a GST-fusion protein corresponding to amino acids 289-538 of LSD1 of human origin
- recommended for detection of LSD1 of mouse, rat and human origin by WB, IP, IF and IHC(P)
- m-IgG1 BP-HRP is the preferred secondary detection reagent for LSD1 Antibody (2D6) for WB and IHC(P) applications. This reagent is now offered in a bundle with LSD1 Antibody (2D6) (see ordering information below).
QUICK LINKS
SEE ALSO...
LSD1 Antibody (2D6) is a mouse monoclonal IgG antibody that detects lysine-specific histone demethylase 1 (LSD1) in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and immunohistochemistry. Anti-LSD1 antibody (2D6) recognizes a protein that plays a crucial role in regulating chromatin structure and transcription by removing methyl groups from histone H3, thereby influencing gene expression and maintaining the epigenetic state of the cell. LSD1′s ability to dynamically regulate histone methylation is vital for cellular processes such as differentiation and development, allowing precise control of gene activity in response to various signals. LSD1 contains a SWIRM domain, a flavin adenine dinucleotide (FAD)-binding motif, and an amine oxidase domain, which are essential for enzymatic function. LSD1 interacts with CoREST, a corepressor that enhances demethylation activity and protects against degradation, highlighting the importance of protein-protein interactions in modulating function. LSD1′s co-localization with the androgen receptor in prostate cells underscores a role in androgen-receptor-dependent transcription, making LSD1 a significant player in both normal physiology and cancer biology.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
LSD1 Antibody (2D6) References:
- LSD1 inhibition sustains T cell invigoration with a durable response to PD-1 blockade. | Liu, Y., et al. 2021. Nat Commun. 12: 6831. PMID: 34819502
- CSF3R and SETBP1 getting high on LSD1. | Zhao, H. and Deininger, MW. 2022. Blood. 140: 529-530. PMID: 35951346
- Recent advances of LSD1/KDM1A inhibitors for disease therapy. | Zhang, C., et al. 2023. Bioorg Chem. 134: 106443. PMID: 36857932
- LSD1 promotes prostate cancer reprogramming by repressing TP53 signaling independently of its demethylase function. | Kumaraswamy, A., et al. 2023. JCI Insight. 8: PMID: 37440313
- LSD1 promotes the FSH responsive follicle formation by regulating autophagy and repressing Wt1 in the granulosa cells. | Zhu, Z., et al. 2024. Sci Bull (Beijing). 69: 1122-1136. PMID: 38302330
- RNF20 contributes to epigenetic immunosuppression through CDK9-dependent LSD1 stabilization. | Dong, B., et al. 2024. Proc Natl Acad Sci U S A. 121: e2307150121. PMID: 38315842
- LSD1 inhibition suppresses ASCL1 and de-represses YAP1 to drive potent activity against neuroendocrine prostate cancer. | Mandl, A., et al. 2024. bioRxiv.. PMID: 38328141
- Strategies that regulate LSD1 for novel therapeutics. | Li, M., et al. 2024. Acta Pharm Sin B. 14: 1494-1507. PMID: 38572094
- LSD1 inhibition circumvents glucocorticoid-induced muscle wasting of male mice. | Cai, Q., et al. 2024. Nat Commun. 15: 3563. PMID: 38670969
- Targeting LSD1 in cancer: Molecular elucidation and recent advances. | Cai, W., et al. 2024. Cancer Lett. 598: 217093. PMID: 38969160
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
LSD1 Antibody (2D6) | sc-136174 | 200 µg/ml | $322.00 | |||
LSD1 Antibody (2D6): m-IgG1 BP-HRP Bundle | sc-542645 | 200 µg Ab; 20 µg BP | $361.00 |